All News

FDA2.jpg

FDA Warning on NSAIDs in Pregnancy

FDA

The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring labeling changes for nonsteroidal anti-inflammatory drugs (NSAIDs).

Read Article
podcast logo

RheumNow Podcast – Lupus Delights (9.18.20)

Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

Read Article
COVID infection mask

COVID-19 Risks in Pregnant Women

Jack Cush, MD

There has been little science or evidence regarding the effects of COVID-19 infection on pregnancy and vice versa; and now the recent MMWR addresses the subject with two new reports

Read Article
podcast logo

RheumNow Podcast - ACR Reproductive Health Slides (9-11-20)

Jack Cush, MD

Dr. Jack Cush reviews the 2020 ACR Reproductive Health Guidelines presented all week here on RheumNow. 

Read Article
Very young rheum patients (<21 y.o) may have higher risk for preterm delivery compared to those 21-25 y.o Abstr#1762 #ACR20 @rheumnow https://t.co/NyLEan2sA1

Links:

k dao KDAO2011 ( View Tweet)

The @rheum_covid experience with patients with rheumatic disease who are *pregnant* and get COVID-19 is being presented by Bonnie Bermas from UTSouthwestern #ACR20 Sunday 3pm Eastern https://t.co/eeKqMXgpFx

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

When discussing pregnancy outcomes with your axSpA patients, do you address potential outcomes related to disease in addition to medication concerns? #ACR20 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Adverse pregnancy outcomes risk factors in spondyloarthritis 1⃣Most common - GSA 2⃣IBD symptoms, aggressive/active disease ⬆️risk 3⃣No difference in age or steroid use Healthy mom, healthy baby. @RheumNow #ACR20 Abs#1324

Robert B Chao, MD doctorRBC ( View Tweet)

Pregnancy outcomes in women with AxSpA 4 prospective cohorts in Europe 328 total pregnancies Favorable outcomes overall 1⃣3% pre-eclampsia 2⃣6-9% gestational DM 3⃣0-5% preterm birth rates (similar to WHO rate 9% in Eur) @RheumNow #ACR20 Abs#1498

Robert B Chao, MD doctorRBC ( View Tweet)

#sjogren #syndrome poster session #ACR20 @RheumNow Clinical characteristics: lung, pregnancy,smoking, cervical lesions, anti La, childhood. https://t.co/QN4FVvQrYN
Sole RetamozoSole ( View Tweet)
How pregnancy impacts nr-axSpA disease activity can vary from one woman to another, according to Eric Ruderman, MD, “I’ve had some patients who are better during pregnancy, and some who aren’t,” says Dr. Ruderman. Learn more about pregnancy and nr-axSpA: https://t.co/mC6YcG5lIx

Links:

NM Rheumatology NM_Rheumatology ( View Tweet)

RheumNow Podcast - ACR Reproductive Health Slides (9-11-20) Dr Jack Cush reviews the 2020 ACR Reproductive Health Guidelines This past week we presented an overview to the new 2020 ACR ACR 2020 Reproductive Guidelines - Contraception & Counseling https://t.co/vnPh2EQZ0a https://t.co/T4y69DYIH7

Links:

Dr. John Cush RheumNow ( View Tweet)
Candian study of 376 pregnancies (284 F) with #SLE and drug use: only 24.2% on antimalarials, 8.2% azathioprine, 19.7% steroids &amp; 4.8% on NSAIDs during pregnancy. 1st trimester discontinuations seen in 16.7% of HCQ & 29.2% AZA https://t.co/a1SMwZuSlm

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish registry comparison of 541 PsA 40944 non-PsA pregnancies between 1997-2014, shows PsA pregnancies had increased risks for preterm birth (adj OR 1.63) and caesarean deliveries (OR 1.47), but no increased risks for pre-eclampsia, stillbirth https://t.co/3Udpjhn1pe

Links:

Dr. John Cush RheumNow ( View Tweet)

Discontinuing TNFi before wk 20 is feasible in RA and JIA pregnancy with well- controlled Dz. OTIS study of 490 women compared 25% who D/C TNFi before wk 20 vs 41% taking TNFi after wk 20. D/C TNF not assoc w/ clinical worsening in the 3rd trimester. https://t.co/DtHvQ2rbWY

Links:

Dr. John Cush RheumNow ( View Tweet)

New data on tocilizumab in pregnancy, upshot is: "Tocilizumab concentrations in cord blood and infant serum were 80–90% of those in maternal serum" https://t.co/SEmyTnL7dy

Links:

Dr. John Cush RheumNow ( View Tweet)

Immunomonitoring with microarrays from the SLE PROMISE pregnancy study shows that adverse outcomes (preeclampsia) can be identified by quantifying plasma cell, interferon and neutrophil RNA levels during the pregnancy https://t.co/oLOwkiGhQ2.

Links:

Dr. John Cush RheumNow ( View Tweet)

117 pregnancies exposed to biologics were compared to 585 pregnancies not exposed to biologics; 6% of newborns had ≥1 congenital anomalies. No significant association between biologic exposure and congenital anomalies (HR 1.06; 95%CI 0.46-2.47) was seen. https://t.co/gsKHGiFPOS

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review of Paternal DMARD exposure prior to pregnancy shows no firm evidence of harm with TNFi, ABA, RTX, azathioprine, cyclosporine, HCQ, leflunomide, MTX or mycophenolate mofetil. Data from 84 papers, 611 male exposures, 5986 pregnancies https://t.co/VgEsrXhfdh

Links:

Dr. John Cush RheumNow ( View Tweet)

The PARA study shows among 249 pregnancies (2002-08), breastfeading was less in RA - at 4-6, 12 & 26 wks postpartum 43%, 26% and 9% of the RA breastfed (vs 63%, 46% &; 41% in controls). Many patients D/C breastfeeding so they could start medication. https://t.co/2205YnoHsb https://t.co/mMyLgMNFfM

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×